| Literature DB >> 35464762 |
Mater H Mahnashi1, Bandar A Alyami1, Yahya S Alqahtani1, Ali O Alqarni1, Muhammad Saeed Jan2, Fida Hussain2, Rehman Zafar3, Umer Rashid4, Muhammad Abbas5, Muhammad Tariq6, Abdul Sadiq7.
Abstract
Prostrate knotweed also called Polygonum aviculare is an important edible plant. The polygonum is majorly known for the phenolics and antioxidants. The antioxidants combat the excessive free radicals within the body. The excessive free radicals are implicated in various other diseases like diabetes, Alzheimer's, and inflammation. This study was aimed at exploring the antioxidant bioactives and their derivatizations to produce new molecules with advanced pharmacological features. We have isolated six compounds (1-6) from Polygonum aviculare. Furthermore, rational-based chemical derivatives for compound 5 have been formed for the management of diabetes, Alzheimer's, and inflammation. In preliminary antioxidant studies, all the isolated compounds (1-6) showed potential results against DPPH and ABTS free radicals. Based on the IC50 and chemical nature of the compounds, compound 5 was subjected to derivatization. Keeping the phenolic part of compound 5 unaffected, hydroxy succinimide (5A) and thiazolidinedione (5B) were synthesized. The compound 5A was found to be a potent inhibitor of AChE, BChE, COX-1, COX-2, 5-LOX, and DPPH giving IC50 values of 10.60, 15.10, 13.91, 1.08, 0.71, and 1.05 μM, respectively. The COX-2 selectivity of compound 5A was found at 12.9. The compound 5B was found to be a potent multitarget antidiabetic agent giving IC50 values of 15.34, 21.83, 53.28, and 1.94 μM against α-glucosidase, α-amylase, protein tyrosine phosphatase 1B, and DPPH. Docking studies were performed to manipulate the binding interactions. The docking pose of all the tested compounds was found to have increased binding affinity against all tested targets that supported the in vitro results. Our results showed that Polygonum aviculare is a rich source of antioxidant compounds. The two new derivatives have enhanced pharmacological features to treat diabetes, inflammation, and Alzheimer's disease.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35464762 PMCID: PMC9020998 DOI: 10.1155/2022/3127480
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 7.310
Figure 1Percent ABTS and DPPH inhibition activities of isolated compounds (1–6).
| Comp No. | Structure | ABTS IC50 | DPPH IC50 |
|---|---|---|---|
| 1 |
| 7.43 | 8.19 |
| 2 |
| 3.005 | 1.61 |
| 3 |
| 12.60 | 10.27 |
| 4 |
| 4.63 | 3.19 |
| 5 |
| 8.28 | 2.12 |
| 6 |
| 9.55 | 9.99 |
| Ascorbic acid | 0.211 | 0.840 | |
Scheme 1Enzymatic activities of compound 5A.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| Sample | AChE IC50 | BChE IC50 | SI | COX-1 IC50 | COX-2 IC50 | SI | 5-LOX IC50 | DPPH IC50 |
| 5A | 10.60 ± 1.03 | 15.10 ± 1.21 | 1.42 | 13.91 ± 1.67 | 1.08 ± 0.05 | 12.9 | 0.71 ± 0.10 | 1.05 ± 0.51 |
| Galantamine | 4.0 ± 0.10 | 15.0 ± 0.67 | 3.75 | — | — | — | — | — |
| Diclofenac | 4.48 ± 0.10 | 10.80 ± 0.71 | 2.4 | — | ||||
| Zileuton | — | — | — | — | — | — | 5.29 ± 0.19 | — |
| Ascorbic acid | — | — | — | — | — | — | — | 0.840 ± 0.14 |
In vitro antidiabetic activities of compound 5B.
|
| ||||
|---|---|---|---|---|
| Sample |
|
| PTP1B IC50 | DPPH IC50 |
| 5B | 15.34 ± 1.08 | 21.83 ± 1.10 | 53.28 ± 1.16 | 1.94 ± 1.20 |
| Acarbose | 10.60 ± 0.21 | 12.71 ± 0.08 | — | — |
| Ursolic acid | — | — | 3.50 ± 0.23 | — |
| Ascorbic acid | — | — | — | 0.840 ± 0.04 |
Binding energies, score, and interaction types of synthesized compounds (1-6) with amino acid residues at active site.
| Compound | Binding energy (Kcal/mol) | Score | Types of interactions | Amino acid residues |
|---|---|---|---|---|
| 1 | -5.264 | -49.392 | Hydrogen bonds, polar bonds, Van der Waal forces, | His A: 42, His A: 60, Val A: 204, Val A: 208, Asn A: 205, Arg A: 209 |
| 2 | -6.987 | -33.427 |
| His A: 60, His A: 204, Val A: 218 |
| 3 | -5.368 | -37.856 |
| His A: 42, His A: 60, Val A: 204, Val A: 218, Phe A: 227 |
| 4 | -7.124 | -39.834 | Conventional hydrogen bond, carbon-hydrogen bond, | His A: 60, His A: 204, His A: 208, Met A: 215, Val A: 218 |
| 5 | -5.427 | -41.347 |
| His A: 42, Val A: 204, His A: 205, Asn A: 205, Phe A: 227 |
| 6 | -4.125 | -37.785 | Conventional hydrogen bond, carbon-hydrogen bond, | His A: 42, His A: 204, Ala A: 221, Phe A: 227, Arg A: 209 |
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11